Crystal Form ASK1 Inhibitor Stability Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ASK1-related diseases lack effective inhibitors that can stabilize and enhance the bioavailability of therapeutic compounds, particularly in forms resistant to light, heat, and humidity, with limited solubility and stability.
Innovation Solution
The development of crystal forms A, B, C, and D of a compound of formula (I), characterized by specific X-ray powder diffraction patterns, differential scanning calorimetry curves, and thermogravimetric analysis, which exhibit stability, high solubility, and resistance to light, heat, and humidity, facilitating their use in drug preparation for ASK1-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for ASK1-related diseases, then existing therapeutic options are available, but they lack effective inhibitors with stable bioavailability and resistance to light, heat, and humidity
Solution Approach 1:
The patent applies parameter changes by transforming the compound into different crystal forms (polymorphs) with distinct physical and chemical properties. Each crystal form exhibits different stability characteristics, solubility, and resistance to environmental factors such as light, heat, and humidity. This allows selection of the most suitable crystal form for therapeutic application, thereby improving reliability and resistance to harmful factors simultaneously.
Solution Approach 2:
The patent utilizes composite material principles by creating specific crystal structures that combine the parent compound with arranged molecular patterns in the solid state. These crystal forms function as composite structures with enhanced properties compared to the raw compound, providing improved stability, bioavailability, and resistance to degradation from light, heat, and humidity exposure.
2Reliability
If the compound is formulated for therapeutic use, then treatment efficacy can be improved, but solubility and stability remain limited
Solution Approach 1:
The patent employs parameter changes by developing multiple crystal forms with varying solubility and stability parameters. By characterizing each crystal form's physical properties through techniques like XRPD, DSC, and TGA, the invention identifies forms that optimize the balance between solubility and stability, enabling effective drug formulation for ASK1-related diseases.
Data Source
AI summary
Provided are crystal forms A, B, C and D of a compound of formula (I), and application of the crystal forms in the preparation of drugs for treating ASK1-related diseases.